NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee B meeting minutes

**Minutes:** Confirmed

**Date:** Thursday 6 July 2023

**Location:** 2 Redman Place, London, E20 1JQ and via Zoom

## Attendees

Committee members present

1. Dr Charles Crawley (Chair) Present for all items
2. Baljit Singh (Vice-chair) Present for all items
3. Mariana Bacelar Items 5.1 to 6.3.2
4. Dr Daniel Gallacher Present for all items
5. Dr Bushra Hasnie Present for all items
6. Dr Veline L’Esperance Items 1.1 to 6.1.3
7. Dr Warren Linley Items 5.1 to 6.3.2
8. Dr Andrew Makin Items 1.1 to 6.1.3
9. Dr Alistair Patton Present for all items
10. Anna Pracz Present for all items
11. Gabriel Rogers  Present for all items
12. Dr Toby Smith Present for all items
13. Mary Weatherstone Items 1.1 to 6.1.3
14. Nigel Westwood Present for all items
15. Dr Stuart Williams Items 1.1 to 6.1.3
16. Tony Wootton Present for all items
17. Peter Wheatley-Price Items 5.1 to 5.3.2
18. Stella O’Brien Present for all items

NICE staff (key players) present

Jacoline Bouvy, Programme Director Present for all items

Richard Diaz, Associate Director Items 1.1 to 4.3.2 / 6.1 to 6.3.2

Ian Watson, Associate Director Items 5.1 to 5.3.2

Leena Issa, Project Manager Items 1.1 to 4.3.2 / 6.1 to 6.3.2

Jeremy Powell, Project Manager Items 5.1 to 5.3.2

Wajeeha Asim, Administrator Items 1.1 to 4.3.2 / 6.1 to 6.3.2

Rumana Zaman, Administrator Items 5.1 to 5.3.2

Mary Hughes, Heath Technology Assessment Adviser Items 1.1 to 4.3.2

Raphael Egbu, Heath Technology Assessment Analyst Items 1.1 to 4.3.2

Adam Brooke, Heath Technology Assessment Adviser Items 5.1 to 5.3.2

Summaya Mohammed, Heath Technology Assessment Analyst

 Items 5.1 to 5.3.2

Claire Hawksworth, Heath Technology Assessment Adviser Items 6.1 to 6.3.2

Anuja Chatterjee, Heath Technology Assessment Analyst Items 6.1 to 6.3.2

Carl Jackson, Assistant Project Manager Present for all items

Portia Dodds, Coordinator Present for all items

External assessment group representatives present

Archie Walters, [BMJ Technology Assessment Group](http://niceplan2/Appraisals_TestLive/FinalCandCs17.aspx?ACID=3904) Items 1.1 to 4.2.1

Victoria Wakefield, [BMJ Technology Assessment Group](http://niceplan2/Appraisals_TestLive/FinalCandCs17.aspx?ACID=3904) Items 1.1 to 4.2.1

Caroline Farmer, Peninsula Technology Assessment Group Items 5.1 to 5.2.1

Darren Burns, Peninsula Technology Assessment Group Items 5.1 to 5.2.1

Robert Wolff, [Kleijnen Systematic Reviews Ltd](http://niceplan2/Appraisals_TestLive/FinalCandCs17.aspx?ACID=3774) Items 6.1 to xx

Clinical, Patient & NHS England experts present

Derralynn Hughes, Clinical expert nominated by Mucopolysaccharide Society Items 1.1 to 4.1.3

Robin Lachmann, Clinical expert nominated by Royal College of Physicians

 Items 1.1 to 4.1.3

Sophie Thomas, Patient expert nominated by Mucopolysaccharide Society Items 1.1 to 4.1.3

Lorella Terzi, Patient expert nominated by Mucopolysaccharide Society

 Items 1.1 to 4.1.3

Carol-Anne Partridge, Patient Expert, nominated by CDKL5 UK Items 5.1 to 5.1.3

Ben Doak, NHS Commissioning Expert Items 1.1 to 4.2.1 / Items 5.1

 to 5.13

Sam Amin, Clinical Expert, nominated by BPNA Items 5.1 to 5.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The Charles Crawley welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted apologies from Professor David McAllister, Dr Francis Drobniewski, Professor Iolo Doull, Peter Wheatley Price and Rhiannon Owen.

### News and announcements

* 1. **There are 2 public consultations now live on NICE website - deadline for responses COB Tuesday 25 July**.

Part 1: [Updates to NICE’s health technology processes manual](https://www.nice.org.uk/guidance/indevelopment/gid-ngc10018/consultation/html-content)

Part 2: [Revised approach to updating technology appraisal recommendations for COVID-19 medicines](https://www.nice.org.uk/guidance/indevelopment/gid-ngc10019/consultation/html-content)

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Wednesday 7 June 2023.
1. **Appraisal of** **[pegunigalsidase alfa for treating Fabry disease [ID3904]](https://www.nice.org.uk/guidance/indevelopment/gid-ta10790)**
	1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Chiesi Limited.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10790).
		3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by the lead team, Dr Bushra Hasnie (clinical), Tony Wootton (lay) and Gabriel Rogers (cost).
	2. Part 2a – Closed session (members of the public were asked to leave the meeting).
		1. The committee discussed confidential information submitted for this item.
	3. Part 2b – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10790>.
1. **Appraisal of** [**ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]**](https://www.nice.org.uk/guidance/indevelopment/gid-ta10948)
	1. Part 1 – Open session
		1. The Vice-Chair, Dr Baljit Singh, welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Orion Pharma.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10948).
		3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Alistair Patton (clinical), Nigel Westwood (lay) and Peter Wheatley-Price (cost).
	2. Part 2a – Closed session (members of the public were asked to leave the meeting).
		1. The committee discussed confidential information submitted for this item.
	3. Part 2b – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10948>.
1. **Appraisal of** **[daridorexant for treating insomnia [ID3774]](https://www.nice.org.uk/guidance/awaiting-development/gid-ta10888)**
	1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/awaiting-development/gid-ta10888).
		3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Charles Crawley.
	2. Part 2 – Closed session (company representatives, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/awaiting-development/gid-ta10888>.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee B will be held on Wednesday 2 August 2023 and will start promptly at 9:30.